PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00352703|
Recruitment Status : Completed
First Posted : July 17, 2006
Last Update Posted : November 3, 2014
|Condition or disease||Intervention/treatment||Phase|
|Non-Hodgkin's Lymphoma Multiple Myeloma||Drug: Kepivance (Palifermin)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||145 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation|
|Study Start Date :||April 2006|
|Primary Completion Date :||April 2007|
|Study Completion Date :||May 2007|
U.S. FDA Resources
Experimental: Kepivance (palifermin) 60 μg/kg/day IV
60 μg/kg/day IV for 3 consecutive days before the conditioning regimen and 3 consecutive days after the peripheral blood stem cell transplantation.
|Drug: Kepivance (Palifermin)|
- The primary efficacy endpoints are the incidence (%) and duration of severe oral mucositis (WHO grades 3 or 4). [ Time Frame: Up to 40 days ]The study consisted of a screening period of up to 42 days to determine subject eligibility, followed by a treatment period of a maximum of 40 days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00352703
|Study Director:||MD||Biovitrum AB|